Hot Features
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-con... Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38, a novel subcutaneously administered drug formulation of cannabidiol for the treatment of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.01 | 0.657894736842 | 1.52 | 1.55 | 1.44 | 52780 | 1.51463156 | CS |
| 4 | -0.05 | -3.16455696203 | 1.58 | 1.6 | 1.43 | 40303 | 1.50416434 | CS |
| 12 | -0.36 | -19.0476190476 | 1.89 | 2.33 | 1.43 | 74202 | 1.85193638 | CS |
| 26 | 0.12 | 8.51063829787 | 1.41 | 2.33 | 1.23 | 96482 | 1.64972402 | CS |
| 52 | -0.4 | -20.725388601 | 1.93 | 2.33 | 1.23 | 119381 | 1.60940702 | CS |
| 156 | 0.37 | 31.8965517241 | 1.16 | 4.26 | 0.91 | 107765 | 1.98872305 | CS |
| 260 | -1.47 | -49 | 3 | 6.19 | 0.61 | 135027 | 2.26624788 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.